Search Medical Condition
Please enter condition
Please choose location from dropdown

Santander, Cantabria, Spain Clinical Trials

A listing of Santander, Cantabria, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (104) clinical trials

Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Multicenter, non- randomized, open-label, double agent, phase II study of the Spanish Group of CLL (GELLC). Patients with untreated CLL/SLL. Ibrutinib will be administered orally 420 mg (3 x 140 mg capsules) once daily on a continuous schedule on an outpatient basis until disease progression or unacceptable toxicity. After 12 ...

Phase

0.0 miles

Learn More »

Longitudinal Study to Identify Predictive Factors of Post-thrombotic Pulmonary Hypertension

Rationale Pulmonary hypertension (PH) post pulmonary thromboembolisms is a serious and complex disease, is one major cause of pulmonary hypertension (1). It is the most feared late complication of pulmonary thromboembolism (PT) characterized by the organization of thrombotic material within the pulmonary arteries (2). Although a purely mechanical theory is ...

Phase N/A

0.0 miles

Learn More »

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Phase II/III, prospective, multicenter, randomized (1:1), double-blind study to evaluate the efficacy and tolerability of axitinib in patients diagnosed with advanced G1-G2 neuroendocrine tumors (WHO 2010) of nonpancreatic origin that have presented documented disease progression in the 12 months prior to entering the study. In the first part of the ...

Phase

0.0 miles

Learn More »

BAMI. The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction

This is a multinational, multicentre, randomised open-label, controlled, parallel-group phase III study. Its aim is to demonstrate that a single intracoronary infusion of autologous bone marrow-derived mononuclear cells is safe and reduces all-cause mortality in patients with reduced left ventricular ejection fraction(</=45%) after successful reperfusion for acute myocardial infarction when ...

Phase

0.0 miles

Learn More »

International Guillain-Barr Syndrome Outcome Study

GBS is a post-infectious immune-mediated polyradiculoneuropathy with a highly diverse clinical course and outcome despite partially effective forms of treatment(immunoglobulins and plasma exchange). Outcome in patients with GBS has not improved in the last two decades. At present about 10 to 20% of patients remain severely disabled and about 5% ...

Phase N/A

0.0 miles

Learn More »

PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years

Prephase (days -5 to -1) Dexamethasone 10 mg/m2 bolus day EV for 5 days (-5 to -1). Supplementary treatment: hydration minimum 2000 ml / day. allopurinol 300 mg / day. gastric protection (as center). daily monitoring of blood glucose daily monitoring of renal function. Intrathecal treatment (diagnosis and prophylactic / ...

Phase

0.0 miles

Learn More »

Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

Induction Chemotherapy Vincristine (VCR): 1.5 mg/m2 (maximum dose 2 mg) iv days 1, 8, 15 and 22 daunorubicin (DNR) 45 mg/m2 i.v. days 1, 8, 15 and 22 Prednisone (PDN): 60 mg/m2 per day, i.v. or p.o., days 1-27 Imatinib 600 mg p.o. from day 1 until the beginning of ...

Phase

0.0 miles

Learn More »

Pulmonary Embolism as a Cause of COPD Exacerbations

The primary objective is to demonstrate the clinical benefits of an active strategy for the diagnosis and treatment of PE compared to usual care in patients with unexplained exacerbations of COPD who require hospital admission. The secondary objective is to assess the safety of an active strategy for the diagnosis ...

Phase

0.0 miles

Learn More »

The EUROSCA Natural History Study

The key goal of EUROSCA-NHS is to determine and compare the rate of disease progression in SCA1, SCA2, SCA3 and SCA6. To this end, a newly developed and validated ataxia scale (Scale for the Assessment and Rating of Ataxia, SARA) will be used. EUROSCA-NHS has a number of secondary aims ...

Phase N/A

0.0 miles

Learn More »

Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia

Objectives Primary To evaluate the response (complete hematologic response [CHR], complete cytogenetic response [CCyR], major molecular response [MMR] and complete molecular response [CMR] of the combination of ponatinib with standard chemotherapy (according to PETHEMA ALL Ph08 trial) in young patients with Ph+ (BCR-ABL) ALL. To evaluate the event free survival ...

Phase

0.0 miles

Learn More »